logo

For the Inventor, By the Inventor

Macclesfield, United Kingdom

David Huw Davies

This inventor holds 17 USPTO granted patents. Top assignees: Imperial Chemical Industries Limited, Schering Corporation, Zeneca Limited. Active years: 1976-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Huw Davies. Retrieved from https://idiyas.com/inventor/david-huw-davies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 100.0

Average Co-Inventor Count = 2.9

ph-index = 7

Forward Citations = 130(Granted Patents)


Location History:

  • Macclesfield, EN (1976 - 1978)
  • Sutton, GB (1991 - 1993)
  • Macclesfield, GB (1979 - 2003)

Company Filing History:

goldMedal8 out of 3,840 
 
Imperial Chemical Industries Limited
 patents
silverMedal5 out of 1,829 
 
Schering Corporation
 patents
bronzeMedal4 out of 854 
 
Zeneca Limited
 patents
4. 2 out of 80 
 
Ici Pharma
 patents
where one patent can have more than one assignee

Years Active: 1976-2003

Loading Chart...
17 patents (USPTO):Explore Patents
1. 6541491 - 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors (2003-04-01),
2. 6436691 - Chemical compounds (2002-08-20),
3. 6232338 - 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors (2001-05-15),
4. 5985281 - Chemical compounds (1999-11-16),
5. 5232918 - Cephalosporin derivatives (1993-08-03),
6. 5126444 - Intermediates for cephalosporin compounds (1992-06-30),
7. 5064824 - Cephalosporin compounds (1991-11-12),
8. 5019570 - Cephalosporin compounds (1991-05-28),
9. 4443471 - Derivatives of M.139,603 useful as growth promoters (1984-04-17),
10. 4279894 - Streptomyces metabolite (1981-07-21),
11. 4225593 - Growth promotion (1980-09-30),
12. 4180565 - 1-N-substituted derivatives of (1979-12-25),
13. 4141974 - Veterinary method employing certain aureolic acid compounds (1979-02-27),
14. 4085208 - Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and (1978-04-18),
15. 4066752 - 1-Desamino-1-hydroxy and (1978-01-03),

Title: The Innovative Contributions of David Huw Davies

Introduction

David Huw Davies is a prominent inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in cancer therapy. With a total of 17 patents to his name, his work has had a profound impact on medical science.

Latest Patents

Among his latest patents, Davies has developed 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors. These pharmaceutical compositions are designed to inhibit ras farnesylation, which is crucial in cancer treatment. His innovative chemical compounds include Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems that utilize mutated carboxypeptidase B enzymes. These systems are aimed at converting prodrugs into effective antineoplastic drugs, specifically targeting tumor-associated antigens. The preferred enzyme mutant is human pancreatic CPB, which has been modified to enhance its efficacy in cancer therapy.

Career Highlights

Throughout his career, David Huw Davies has worked with notable companies such as Imperial Chemical Industries Limited and Schering Corporation. His expertise in pharmaceutical sciences has led to groundbreaking advancements in cancer treatment methodologies.

Collaborations

Davies has collaborated with esteemed colleagues, including Alan K Mallams and Francis Thomas Boyle. These partnerships have further enriched his research and development efforts in the pharmaceutical industry.

Conclusion

David Huw Davies stands out as a key figure in the realm of pharmaceutical innovation, particularly in cancer therapy. His extensive patent portfolio and collaborative efforts underscore his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…